Why Alzheimer’s May Be a Metabolic Disease

Summary

---

The Metabolic Classroom with Dr. Ben Bikman

Episode: Why Alzheimer’s May Be a Metabolic Disease
Date: March 9, 2026
Host: Dr. Ben Bikman (Metabolic Scientist, Professor of Cell Biology)
Podcast: The Metabolic Classroom (by Insulin IQ)

---

Episode Overview

Dr. Ben Bikman delivers a detailed, practical, and critical mini-lecture about the dominant theories of Alzheimer’s disease. He explains why mounting evidence suggests that Alzheimer’s may fundamentally be a metabolic disorder—specifically, “type 3 diabetes,” or brain-based insulin resistance—rather than a disease driven by brain plaques alone. Dr. Bikman takes listeners through the scientific history, controversies, failures of existing drug treatments, and the potential for new, metabolism-centered approaches to Alzheimer's prevention and mitigation.

---

Key Discussion Points & Insights

1. Historical Background of Alzheimer’s Disease

• Founding Observations:

  • 1906: Dr. Alois Alzheimer identified hallmark "sticky plaques" (amyloid beta) and "tangled fibers" (tau) in the brain of a patient with profound memory loss.
  • This seeded the plaque-centric theory of Alzheimer’s.
  • [02:55] “That was the birth of what we now call Alzheimer’s disease.”

• The Amyloid Cascade Hypothesis:

  • Emerged in the 1990s, suggesting amyloid plaques were the cause of Alzheimer’s, sparking massive research and drug development investments.

2. Cracks in the Paradigm: Plaques as Cause or Consequence?

• Weak Correlation Between Plaques and Disease:

  • Many with plaques show no cognitive impairment; some with Alzheimer’s have few plaques.
  • [05:25] “The amounts and distribution of a beta deposition are only weakly correlated with the clinical expression of the disease."

• Quote:

  • [05:40] “By age 80, as many as 60% of cognitively normal elderly individuals have detectable amyloid in their brains. That is a fundamental problem. If plaques caused dementia, they should track with dementia. They often don’t.” – Dr. Ben Bikman

• Scientific Fraud and Retractions:

  • A pivotal 2006 Nature paper, foundational for amyloid research, was retracted in 2024 due to data fabrication.
  • Large numbers of related papers were also found to contain doctored data, further destabilizing the “plaque hypothesis.”
  • [07:10] “It was eventually retracted in 2024… Now it is the second most highly cited paper that has ever been retracted.”

3. Failures of Amyloid-Targeting Drugs

• Repeated Clinical Failures:

  • From 2003–2021, no new drugs targeting amyloid plaques provided clinical benefit, despite billions spent and intensive research focus.
  • [09:10] “None showed meaningful cognitive benefits. Billions of dollars, but zero new treatments.”

• Controversies in Drug Approval:

  • Aducanumab’s FDA approval in 2021 was highly controversial and reversed in 2024 due to underwhelming results and concerning side effects (brain swelling, microbleeds).
  • [09:30] “It seems increasingly apparent that clearing plaques does not cure the disease… It doesn’t even stop its progression.”

4. A Metabolic Reframing: Alzheimer’s as “Type 3 Diabetes”

• Introduction to Brain Insulin Resistance:

  • Research led by Dr. Suzanne de la Monte demonstrated that disabling the brain's insulin receptors in rats replicates Alzheimer’s-like changes—plaques, tangles, and cognitive decline.
  • [11:00] “She later coined the term type 3 diabetes to describe Alzheimer’s, a form of diabetes that selectively involves the brain…”

• Insulin’s Role in Brain Health:

  • Insulin in the brain is essential for energy supply, neuronal survival, synaptic plasticity, inhibiting tau tangles, clearing amyloid, and neurotransmitter regulation.
  • [13:00] “When brain insulin signaling fails, you get energy starvation of neurons, a runaway of tau phosphorylation inducing the tangles, and you have impaired amyloid clearance.”

• Core Insight:

  • [15:35] “The full picture of Alzheimer’s pathology could be explained as downstream consequences of impaired insulin signaling in the brain. Nothing more, nothing less.”

5. Epidemiology: Diabetes, Insulin Resistance, and Dementia

• Elevated Risk in Diabetics:

  • Meta-analyses consistently show that diabetes significantly raises the risk—by 56–73%—of Alzheimer’s and other dementias.
  • Longer diabetes duration and higher blood sugar further elevate risk, with early-onset diabetes tripling Alzheimer’s risk.
  • [16:26] “A 2025 meta-analysis... found that those with longer diabetes duration had substantially higher dementia risk.”

• Important Nuance:

  • Not everyone with diabetes develops Alzheimer’s, nor do all Alzheimer’s patients have diabetes. There may be both secondary (systemic) and primary (brain-specific, possibly genetic) insulin resistance.

6. Genetics & APOE4: Connecting Genes and Metabolic Dysfunction

• APOE4 as a Metabolic Risk Factor:

  • The APOE4 allele is a major genetic risk factor for Alzheimer’s; it impairs insulin receptor placement on neuron surfaces, reducing insulin signaling independently of blood insulin.
  • [19:02] “APOE4 may be fundamentally and directly impairing the brain’s insulin signaling system, creating a condition of brain specific insulin resistance with a very clear genetic origin.”

• Quote:

  • [20:44] “The brain starves for energy… Amyloid accumulates because the clearance machinery that depends on insulin signaling has broken.”

7. Alternative Brain Fuel: Ketones and Metabolic Rescue

• Glucose Starvation – Ketone Rescue:

  • The Alzheimer's brain loses capacity to process glucose but retains the ability to utilize ketone bodies for energy—without needing insulin.
  • PET imaging (Cunnane et al.) shows that, while glucose uptake is reduced by up to 32% in Alzheimer’s brains, ketone metabolism remains intact.
  • [25:26] “In mild to moderate Alzheimer’s disease, brain glucose uptake was up to 32% lower… But ketone uptake in metabolism was completely normal.”

• Molecular Evidence:

  • Dr. Bikman’s lab found impaired glucose-burning gene activity in all brain cell types in Alzheimer’s, but near-normal gene activity for ketone metabolism.
  • [28:40] “The molecular machinery for burning glucose was broadly impaired... But ketolytic gene expression was not significantly altered.”

• Dietary Implications:

  • Ketones are only produced with low insulin—during fasting or carbohydrate restriction. High-carb diets keep ketone levels near zero, stranding the Alzheimer’s brain in an energy crisis.

• Clinical Trials & Exogenous Ketones:

  • Early studies show ketone supplementation improves cognitive function, especially in those without APOE4, but benefits all.
  • [30:34] “There is a study finding that at 90 days with patients taking an MCT-based ketogenic compound, patients who achieved ketosis showed significant improvements on cognitive assessments…”

8. Prevention & Hope: Practical Takeaways

• Prevention Decades Before Disease:

  • Metabolic dysfunction associated with Alzheimer’s can be detected decades before symptoms—examples include young women with PCOS (another insulin-resistant state).

• Lifestyle Change is Key:

  • Improving insulin sensitivity (low-carb diet, exercise, weight management) likely provides the best-known prevention strategy.

• APOE4 Consideration:

  • Genetic risk is not destiny, but those with APOE4 should be especially diligent about metabolic health and may benefit most from carbohydrate restriction.

• Quote:

  • [33:42] “We don’t yet have a drug that stops Alzheimer’s, but we may have lifestyle strategies that substantially reduce the risk of ever developing it.”

---

Notable Quotes & Memorable Moments

• [05:40] “By age 80, as many as 60% of cognitively normal elderly individuals have detectable amyloid… If plaques caused dementia, they should track with dementia. They often don’t.” – Dr. Ben Bikman
• [07:10] “It was eventually retracted in 2024… Now it is the second most highly cited paper that has ever been retracted.”
• [09:30] “It seems increasingly apparent that clearing plaques does not cure the disease… It doesn’t even stop its progression.”
• [15:35] “The full picture of Alzheimer’s pathology could be explained as downstream consequences of impaired insulin signaling in the brain. Nothing more, nothing less.”
• [20:44] “The brain starves for energy… Amyloid accumulates because the clearance machinery that depends on insulin signaling has broken.”
• [25:26] “In mild to moderate Alzheimer’s disease, brain glucose uptake was up to 32% lower… But ketone uptake in metabolism was completely normal.”
• [33:42] “We don’t yet have a drug that stops Alzheimer’s, but we may have lifestyle strategies that substantially reduce the risk of ever developing it.”
• [34:59] “The metabolic theory of Alzheimer’s does something the plaque theory struggled to do. It really tells a complete mechanistic story from cell biology through epidemiology. It connects all the dots and… opens the door for… much more meaningful interventions in the future.”

---

Key Timestamps of Important Segments

| Time | Segment | |----------|----------------------------------------------| | 02:00 | Historical foundation of Alzheimer’s | | 04:30 | Plaque hypothesis and early skepticism | | 07:00 | Scientific fraud, pivotal retraction | | 09:10 | Drug trial failures and the Aducanumab story | | 11:00 | Introduction of Type 3 Diabetes theory | | 13:00 | Insulin’s roles in healthy brain function | | 15:35 | “Metabolic reframing” summarized | | 16:26 | Epidemiology: diabetes, dementia risk | | 19:00 | APOE4 and impaired insulin signaling | | 25:26 | Glucose vs. ketone PET imaging findings | | 28:40 | Dr. Bikman’s gene expression research | | 30:34 | Clinical results with ketone supplements | | 33:42 | Practical prevention and lifestyle advice | | 34:59 | Closing reflection on shifting paradigms |

---

Conclusion

Dr. Bikman challenges the mainstream “plaque hypothesis” of Alzheimer’s, pointing to major scientific, clinical, and epidemiological weaknesses, including infamous research fraud. Instead, he lays out a coherent mechanistic argument that Alzheimer’s is, at its core, an issue of brain insulin resistance—a phenomenon sometimes referred to as “type 3 diabetes.”
He emphasizes that this view better fits the molecular and clinical data, opens new therapeutic hopes—especially through dietary change and use of ketones as neural fuel—and empowers listeners and their loved ones to take preventative action, decades before dementia might appear.

“Science advances when honest researchers are willing to follow the data wherever it leads, even when it may be uncomfortable… The metabolic theory of Alzheimer’s opens the door for much more meaningful findings and interventions in the future.”
— Dr. Ben Bikman [34:59]

---

For more detailed information or to share this episode, visit BenBikman.com or InsulinIQ.com

Transcript

[Capital One Bank Spokesperson]

With no fees or minimums on checking accounts, it's no wonder the Capital One bank guy is so passionate about banking. With Capital One, if he were here, he wouldn't just tell you about no fees or minimums. He'd also talk about how most Capital One cafes are open seven days a week to assist with your banking needs. Yep, even on weekends, it's pretty much all he talks about. In a good way. What's in your wallet? Term supply see capitalone.com bank capital1na member FDIC

[Ben Bickman]

knock knock. Ooh, who's there? A Boost Mobile expert here to deliver and set up your all new iPhone 17 Pro designed to be the most powerful iPhone ever.

[Skyrizi Advertisement Voice]

You called that a knock knock joke?

[Ben Bickman]

This isn't a joke. Boost Mobile really sends experts to deliver and set up your phone at home or work.

[Skyrizi Advertisement Voice]

Okay. It's just that when people say knock knock, there's usually a joke to go with it.

[Ben Bickman]

Like I said, this isn't a joke.

[Skyrizi Advertisement Voice]

So the knock knock was just you knocking?

[Ben Bickman]

Yeah, that's how doors work.

[Skyrizi Advertisement Voice]

Get the new iPhone 17 Pro delivered and set up by an expert wherever you are. Delivery available for select devices purchased at boostmobile.com, terms apply. My son loves to fly kites, but my active psoriatic arthritis can sometimes hold me back. Now with Skyrizi to treat my skin and joints, I'm ready to go. Skyrizi Risankizumab RZA a prescription only 150mg injection for adults. Helps with less joint pain, stiffness, swelling and fatigue. For those who also have plaque psoriasis, 90% clearer skin is possible with just four doses a year. After two starter doses,

[Instacart / Workday Advertisement Voice]

don't use if allergic to Skyrizi. Serious allergic reactions and an increased risk of infection or a lower ability to fight them may occur. Before treatment, your doctor should check for infection and tuberculosis. Tell your doctor if you have an infection or symptoms such as fever, sweats, chills, muscle aches or cough, or if you plan to or recently received a vaccine.

[Skyrizi Advertisement Voice]

With Skyrizi, there's nothing like clearer skin and better movement. And that means everything. Ask your doctor about Skyrizi today and visit skyrizi.com or call 1-866-Skyrizi to learn more.

[Ben Bickman]

Foreign. Welcome to the Metabolic Classroom Podcast. I'm Ben Bickman. Thanks for letting me be your guest professor for the next few minutes. Don't worry about any pop quizzes. I'm here to simply make the science of metabolism clear, practical and engaging. Welcome back to the Metabolic Classroom. Ben. I'm Ben Bickman, metabolic scientist and professor of cell biology. Today's mini lecture aims to teach you about the metabolism of Alzheimer's disease and why a growing body of evidence suggests this devastating condition may be, at its root, a metabolic disorder. Now, you might be thinking, Ben, isn't Alzheimer's all about plaques? About sticky proteins in the brain? That's exactly what most of us were taught, or at least what we've heard and what most of the scientific community has believed and funded for decades. But I want to walk you through a fascinating and, if I'll be honest, somewhat troubling story about how a dominant scientific theory was built on questionable foundations, how the drugs it inspired have largely disappointed, and how a metabolic framework may offer the explanations that the plaque theory never could. But as usual, let's start from the beginning. It starts. The story starts in 1906 when a German psychiatrist and neuroanatomist, so a guy who would look at brains named Alois Alzheimer described a 51 year old woman with profound memory loss and disorientation, all of the cardinal signs that we would associate with Alzheimer's disease. When she died, he examined her brain under a microscope and found two striking abnormalities. Sticky plaques between the neurons and tangled fibers inside them. That was the birth of what we now call Alzheimer's disease. For most of the 20th century, research into these findings was slow. But in 1992, a landmark hypothesis emerged. The amyloid cascade hypothesis. The idea was nice. A protein called amyloid beta, or a beta accumulates between neurons and forms plaques. These plaques were proposed to trigger a cascade neuro inflammation, something called a tau tangle. That was those tangles, the tau tangle, formation, neuronal death, and ultimately dementia. The plaques, not just a marker of the disease, but as the theory went, the plaques are the disease. This became the dominant paradigm, in fact, I could say the only paradigm. Research funding poured in. By 2021, NIH funding for studies centered on amyloid or related pathologies with Alzheimer's disease reached nearly $300 million per year. The entire field oriented itself around this theory, and the goal became finding ways to clear or prevent those plaques. But there were problems almost from the beginning. Problem number one, you can have lots of plaques and no cognitive decline whatsoever. Autopsy studies have found abundant amyloid deposits in people who were cognitively completely normal at the time of their death. Conversely, some people with clinical Alzheimer's disease had relatively modest plaque burden. As researchers put it in one particular published manuscript, the amounts and distribution of a beta deposition are only weakly correlated with the clinical expression of the disease. That's the end of the quote. And by age 80, as many as 60% of cognitively normal elderly individuals have detectable amyloid in their brains. That is a fundamental problem. If plaques caused dementia, they should track with dementia, they often don't. Now, let me tell you a story that should shock you. It makes these things get even more troubling because it did shock the scientific community. In 2006, a neuroscience group at the University of Minnesota published a big paper, a landmark paper in a very big journal called Nature. The paper described a specific form of amyloid beta and appeared to show for the first time a direct cause and effect relationship between this protein and memory impairment. This was in animals. It was exactly what the field had been waiting for. It was the scientific smoking gun. The paper became one of the most cited Alzheimer's papers of the 21st century. It was cited and has been cited. Well, it gets complicated, as I'll get to in a moment, thousands of times. It buoyed confidence in the amyloid hypothesis at a moment when it was facing a lot of skepticism after a lot of failed drug trials. More on that in a moment. It shaped research priorities and helped direct hundreds of millions of dollars in NIH funding. Then, just a few years ago, in 2022, an investigation identified more than 20 papers with data that appeared to have been digitally manipulated to fabricate or exaggerate results. The 2006 Nature paper was eventually retracted in 2024, nearly about 20 years after its publication. In fact, now it is the second most highly cited paper that has been ever retracted. Now, defenders of the amyloid hypothesis will argue that that the hypothesis doesn't rest solely on this one paper. The genetics of familial Alzheimer's, the connection with down syndrome, and other lines of evidence, they would say, support a role for amyloid. But the critical point is that this one paper propped up a very weakening hypothesis at a moment of crisis. It directed the funding, it shaped drug development strategies, and it really reinforced a tunnel vision, if you will, in a field that desperately needed to consider other explanations. And the broader pattern of fraud in Alzheimer's research didn't actually stop there. Subsequent investigation found that an astonishing 132 scientific papers published between 1997 and 2023 by a former director of the Division of Neuroscience at the NIH contained doctored data. So if the plaque theory were correct, if amyloid beta deposits were the primary cause of Alzheimer's, then removing them should help patients. But let's look at that track record. For nearly two decades from 2003 to 2021, not a single new drug was approved for Alzheimer's disease. Trial after trial of anti amyloid agents failed to meet the end points. These are going to be drugs with the suffix umab, like Solena's umab, ganternarumab, krenizunab and similar names. But if you hear the suffix umab, it's going to fit into this family of drug. None showed meaningful cognitive benefits. Billions of dollars, but zero new treatments. Then in 2021 came another one, the latest addition. Add you can you mab. It was approved by the FDA then, and it was approved by the FDA through a very controversial accelerated pathway. Despite the fact that its own advisory committee concluded that efficacy had not been demonstrated. Two large phase three trials gave conflicting results. One showed a modest slowing of decline at high doses. The other didn't show anything. And in fact, there were consequences like brain swelling and microbleeds in over a third of the people who were on the drugs. And it was eventually pulled from the market in 2024, just about 30 months or so after it was initially approved. It seems increasingly apparent that clearing plaques does not cure the disease. It doesn't even stop its progression. What does this tell us? It tells us that amyloid plaques may be a consequence or even a bystander in Alzheimer's disease, not the root cause. There is something deeper going on with the plaque theory crumbling under its own weight. We do have an opportunity for a different framework to gain some momentum, and that's exactly what's been happening. I frankly find the alternative view much more compelling because it is anchored in mechanism. It is supported by extensive epidemiology and aligned with what we know about insulin's profound effects on the brain. The key idea, Alzheimer's disease may be a form of brain specific insulin resistance. In 2005, Dr. Suzanne Delamante of Brown University published a pivotal finding in her laboratory. When she knocked out or removed the insulin receptor in the brain of rats, she induced a state that closely resembled Alzheimer's disease. There was an accumulation of the amyloid protein, there was the tau phosphorylation in the tangles, and there was, most importantly, the cognitive impairment. She later coined the term type 3 diabetes to describe Alzheimer's, a form of diabetes that selectively involves the brain sharing molecular and biochemical features with both type 1 and type 2 diabetes. And that would be the hyperglycemia and the targeted insulin resistance. Delamante and her colleagues demonstrated that brain insulin and brain insulin like growth factor, which has this Kind of overlapping signaling. If you remove that or reduce that signaling that you induced a resistance to the signal, it would progressively promote an increased severity of Alzheimer's disease. And then using post mortem brain tissue, they showed that the more advanced the Alzheimer's pathology, the worse the brain. Insulin signaling. This was demonstrated at the level of insulin gene expression, insulin receptor binding. So the degree to which insulin can lock onto its receptor, as well as the downstream signaling or the cascade of events that happens within the neurons when insulin binds to its receptor. Now, why does insulin matter so much to the brain? Well, insulin is not just a blood sugar or blood glucose regulator in the brain. Insulin does indeed help promote some glucose uptake in some brain cells through the GLUT4 or the glucose transporter 4. But it also supports neuronal survival and synaptic plasticity. It does regulate glucose metabolism, including the degree to which the neurons are burning glucose for ATP. It inhibits tau hyperphosphorylation, which is the main driver of the neurofibrillary tangles. And it facilitates beta amyloid clearance via an enzyme called insulin degrading enzyme. And lastly, insulin modulates neurotransmitter systems including acetylcholine. So when brain insulin signaling fails, you get energy starvation of neurons, you get a runaway of tau phosphorylation inducing the tangles, and you have impaired amyloid clearance.

[Instacart / Workday Advertisement Voice]

We all prefer things a certain way, like groceries. If you want groceries just how you like them, you gotta try Instacart. They have a new preference picker that lets you pick how ripe or unripe you want your bananas. Shoppers can see your preferences upfront, helping guide their choices. Because when it comes to groceries, the details matter. Instacart get groceries just how you like.

[Skyrizi Advertisement Voice]

My son loves to fly kites, but my active psoriatic arthritis can sometimes hold me back. Now with Skyrizi to treat my skin and joints, I'm ready to go. Skyrizi Rizzen Kiss Mabriza a prescription only 150mg injection for adults. Helps with less joint pain, stiffness, swelling and fatigue. For those who also have plaque psoriasis, 90% clearer skin is possible with just four doses a year. After two starter doses,

[Instacart / Workday Advertisement Voice]

don't use if allergic to Skyrizi. Serious allergic reactions and an increased risk of infections or a lower ability to fight them may occur. Before treatment, your doctor should check for infection and tuberculosis. Tell your doctor if you have an infection or symptoms such as fever, sweats, chills, muscle aches or cough, grief or if you plan to or recently received

[Skyrizi Advertisement Voice]

a vaccine with Skyrizi, there's nothing like clearer skin and better movement. And that means everything. Ask your doctor about Skyrizi today and visit skyrizi.com or call 1-866-Skyrizi to learn more.

[Ben Bickman]

In other words, the full picture of Alzheimer's pathology could be explained as downstream consequences of impaired insulin signaling in the brain. Nothing more, nothing less. This is a profound reframing of the paradigm. Plaques may not be the cause. They may be the exhaust fumes from a brain that has lost the ability to use insulin properly. In other words, it's a consequence, not a cause. Now let's step back and look at the population level data. As much as I'm loathe to ever rely on epidemiology, when the epidemiology is in sync with the mechanism, then you have a powerful data perspective. If insulin resistance drives Alzheimer's, then people with type 2 diabetes, who of course have insulin resistance, should be at elevated risk. And they are. The evidence here is striking. A major Meta analysis of 28 prospective observational studies found that individuals with diabetes have a pooled relative risk of 1.56, so 56% increase for developing Alzheimer's specifically and 1.73 for any type of dementia. And this is a consistent signal across a lot of different populations. In fact, a more recent Meta analysis from 2024 covering over 10 million individuals with diabetes, found a 59% increased risk of dementia. That's pretty consistent with earlier findings. And then another large study out of the Netherlands, one of the most respected epidemiological studies in the world, found that diabetes nearly doubled the risk of dementia. And it's not just the presence of diabetes, it's the metabolic severity that tracks with the risk. A 2025 meta analysis of over 7 million individuals with type 2 diabetes found that those with longer diabetes duration had substantially higher dementia risk. Higher hemoglobin A1C was associated with hazard ratios as high as 3.88. In the most extreme category, diabetes diagnosed before age 50 was associated with a hazard ratio of 3 fold higher risk for Alzheimer's compared to age matched controls. But here's an important nuance that I need to admit to. Not all people with type 2 diabetes develop Alzheimer's. All Alzheimer's patients have type 2 diabetes. The overall framework, again initially posited by Delamante's group, accounts for this by distinguishing between systemic insulin resistance, which can secondarily impair the brain, and primary brain insulin resistance, where you just have a more targeted insulin resistance of the brain, perhaps driven by a random genetic or familial susceptibility. The two can occur together and certainly can amplify each other, but either alone can move someone toward neurodegeneration. Now let's talk about one of the most important genetic risk factors in Alzheimer's disease. The APOE4 allele, or that variant of a gene. The apolipoprotein E Gene comes in three main variants, E2, E3 and E4. Carrying one copy of APOE4 increases your risk of late onset Alzheimer's by three to fourfold. Carrying two copies increases it up to 15 fold. So about 50% of Alzheimer's patients carry at least one APOE4 allele. The traditional explanation for why APOE4 is dangerous centers on the role in amyloid clearance. The E4 isoform is less efficient at helping clear amyloid beta from the brain. But here's the fascinating question that metabolic researchers have been pursuing. What if Apoe4's primary danger is that it directly impairs insulin signaling? In 2017, a study published in the journal Neuron provided a mechanistic answer. The researchers showed that in neurons, ApoE4 physically interacts with the insulin receptor and traps the insulin receptor inside the cell. The inside these little compartments called endosomes, which then prevents the receptor from reaching the cell surface where it would normally respond to insulin. The insulin receptor gets locked in or sequestered inside the neuron, where it's essentially inaccessible to the insulin that's waiting outside the cell. The result of this is obvious. You of course have impaired insulin signaling and all of the consequences that comes with it. So impaired glucose uptake, impaired glucose metabolism and producing ATP generation, impaired regulation of tau phosphorylation and all the other things I mentioned earlier. Even if blood insulin is fine and even if insulin is working well elsewhere, the effect they noticed was age dependent and it worsened with diet induced obesity in the particular animal model. In aging ApoE4 mice, as ApoE4 protein aggregated and the function of the cell deteriorated, the inhibitory effects of insulin signaling became even more severe. Subsequent work has reinforced this studies in human APOE targeted replacement mice. So using a human form of APOE4 in the mice, they found that APOE4 expression was linked to lower brain insulin signaling, lower brain glucose content, and higher overall outside of the brain insulin levels or in the brain blood, but not in the brain cells. Crucially, when researchers attempted to to boost cognition by inserting insulin through a separate mechanism, the ApoE4 carriers showed little to no benefit. Their neurons couldn't respond even to supplemental insulin because the receptor was trapped post mortem human brain Studies by Delamante and colleagues found that homozygous ApoE4 carriers, so people who had both copies from their mom and their dad, they showed earlier stage reductions in brain insulin expression. The brain was running low on insulin before the Alzheimer's pathology even reached advanced or noticeable stages. This suggests APOE 4 sets the stage for metabolic failure of the brain long before clinical symptoms appear. Think about what this means. Apoe4 isn't just a problem because it fails to clear amyloid. ApoE4 may be fundamentally and directly impairing the brain's insulin signaling system, creating a condition of brain specific insulin resistance with a very clear genetic origin. The brain starves for energy and of course at the same time tau goes haywire, inducing all the neurofibrillary tangles. Neurons are dying and yes, amyloid accumulates because the clearance machinery that depends on insulin signaling has broken.

[Skyrizi Advertisement Voice]

My son loves to fly kites, but my active psoriatic arthritis can sometimes hold me back. Now with Skyrizi to treat my skin and joints, I'm ready to go. Skyrizi Risankizumab RZA a prescription only 150mg injection for adults helps with less joint pain, stiffness, swelling and fatigue. For those who also have plaque psoriasis, 90% clearer skin is possible with just four doses a year. After two starter doses,

[Instacart / Workday Advertisement Voice]

don't use if allergic to Skyrizi. Serious allergic reactions and an increased risk of infections or a lower ability to fight them may occur. Before treatment, your doctor should check for infection and tuberculosis. Tell your doctor if you have an infection or symptoms such as fever, sweats, chills, muscle aches or cough, or if you plan to or recently received a vaccine.

[Skyrizi Advertisement Voice]

With Skyrizi, there's nothing like clearer skin and better movement. And that means everything. Ask your doctor about Skyrizi today and visit skyrizi.com or call 1-866-Skyrizi to learn more.

[Capital One Bank Spokesperson]

With no fees or minimums on checking accounts, it's no wonder the Capital One bank guy is so passionate about banking with Capital One. If he were here, he wouldn't just tell you about no fees or minimums. He'd also talk about how most Capital One cafes are open seven days a week to assist with your banking needs. Yep, even on weekends, it's pretty much all he talks about in a good way. What's in your wallet? Terms apply. See capitalone.com bank capital1na member, FDIC.

[Ben Bickman]

Now, as much as the story I've been telling has maybe been a bit discouraging, let's take a more helpful turn because there is some fascinating science here that can leave someone quite optimistic. Because while the brain insulin resistance progressively shuts down the ability of neurons to use glucose, there is another fuel that the brain can use, one that doesn't require insulin signaling at all. That fuel is ketones. Let me explain why this matters so much. Glucose enters the brain and gets taken up by neurons through glucose transporter, one of which the brain has several requires insulin. When insulin signaling is broken, as we now know it is in the Alzheimer's brain, glucose uptake falters and metabolic flux through the glycolytic or glucose burning pathway kind of slows to a crawl. Brain imaging confirms this vividly. PET or PET scans using fdg, which is, which stands for fluorodeoxyglucose, which is a radioactive glucose that you can use for imaging. So you can get a picture of this type of glucose with a PET scan. So PET and fdg, you can couple them together. It has been used to map the brain energy metabolism for decades. It's a, it's a well established technology in Alzheimer's disease. FDG PET scans show striking regional reductions in glucose uptake. And crucially, these deficits are detectable years before clinical symptoms of any kind of cognitive decline start to emerge. The brain is starving for energy long before the person knows anything is wrong. But the brain is a metabolic hybrid. Yes, it uses glucose as a fuel when it can, but it also uses ketones whenever they are available. To make that very clear. The brain is opportunistic. It's going to use whichever of the two fuels is available, and if both are equally available, it prefers ketones. This is very clear. We've had decades of evidence showing this from as far back as Dr. Cahill's work. C A H I L L I invite anyone to look at his work on brain metabolism. But here's the critical question. Does the same thing happen with glucose metabolism or that happens to glucose metabolism? Does it also happen to ketones? Ketones primarily beta Hy beta hydroxybutyrate and the other one, acetoacetate. But BHB beta hydroxybutyrate is the main fuel. These are transported into the brain through monocarboxylate transporters, appropriately named mcts. This is an entirely separate uptake pathway from glucose and importantly, it can work completely independently of insulin signaling. And once inside neurons, ketones like bhb, are burned and they rapidly generate ATP again, all without needing to pass through insulin dependent machinery or signaling that is impaired in Alzheimer's ketones literally bypass the broken steps. Research from Steven Cun's group has been particularly illuminating. Using a specialized PET tracer for ketones, his group has directly imaged brain ketone metabolism in Alzheimer's patients alongside the glucose PET scans. What they found was striking. In mild to moderate Alzheimer's disease, brain glucose uptake was up to 32% lower in key regions involved in cognition compared to healthy controls. But ketone uptake in metabolism was completely normal. I don't mean even modestly preserved, but totally normal. Three separate studies from this group confirms these findings. The Alzheimer's brain, despite being in an energy crisis from glucose failure, retains its full capacity to take up and use ketones. Think about what this means. The metabolism of the brain is not uniformly disrupted. The specific problem is in glucose uptake and utilization. The insulin dependent pathway, the ketone pathway, remains intact. The brain is starving in a sea of glucose it can't use, while the alternative rescue fuel sits waiting to be available. If only it is available. Even in my own lab. We've made some modest contributions in this space. In a paper we published in the journal Alzheimer's and Dementia, which is a good journal we published in 2021, my team here at BYU set out to go beyond the PET imaging and ask what is happening at the level of gene Expression? We analyzed RNA sequencing data from over 240 post mortem Alzheimer's and control brains. We analyzed gene expression across four distinct cell types of the brain. And we looked at genes governing two metabolic pathways, glycolysis, glucose burning and ketolysis or ketone burning. Across every cell type examined, genes governing glycolysis were significantly down regulated. In Alzheimer's brains, the molecular machinery for burning glucose was broadly impaired across every neural cell type that we examined. That confirmed a lot of what others had shown, but at a more mechanistic level. But the ketolytic story was different and much more. Hopefully in neurons, astrocytes and microglia, ketolytic gene expression was not significantly altered. It was almost totally normal. There were some modest changes here and there, but overall the pathways of ketolysis were functioning normal. And that brings me to what I consider to be one of the most underappreciated metabolic realities of modern life. Ketones are produced when insulin levels are low. Primarily, of course, that means during fasting or carbohydrate restriction, when insulin is chronically elevated. As it is in most people eating a high carb diet that is refined high in refined starches and sugars, ketone production is essentially zero. The liver does not release meaningful ketones whenever insulin is high. So here's the tragedy in plain language. The Alzheimer's brain is progressively losing its ability to use glucose, but it retains the molecular machinery to use ketones. But because of the way most people eat, ketone levels are near zero essentially all the time the brain is stranded. Now, of course, this is one reason why you would make the case for exogenous ketones in the form of GO BHB or any form of straight bhb. Clinical trials reinforce this therapeutic potential. Whether it's exogenous ketones or, or whether it's MCT based supplements or straight MCT oil, which is highly ketogenic, it can improve the disease outcomes. There is a study finding that at 90 days with patients taking an MCT based ketogenic compound, patients, patients who achieved ketosis showed significant improvements on cognitive assessments, with the most pronounced effects coming in those who did not have APOE 4, but still they found benefits in those individuals. There are multiple studies being published essentially at this point every year, with exogenous ketones gaining more and more attention, particularly bhb. I am very optimistic that we're going to have a lot of good, hopeful findings in the near future. So what does all this mean practically for you, for your family, for the people you may care about? First, the metabolic underpinnings of Alzheimer's are likely being established decades before symptoms appear. One of Dr. Stephen Cunane's findings, in fact, was that in young women in their 20s, they could already detect just lowered brain glucose uptake and metabolism in these young women with pcos, which, as you know, being as informed as you are is in fact another symptom of insulin resistance. Second, anything that improves insulin sensitivity, like going on a low carb diet by reducing your carbs, exercising better, etcetera, May represent the most meaningful Alzheimer's prevention strategy available. We don't yet have a drug that stops Alzheimer's, but we may have lifestyle strategies that substantially reduce the risk of ever developing it. Third, the Apoe 4 story reminds us that genetics isn't destiny, but it does require attention. If you carry the APOE4 gene, your brain is more susceptible to impaired insulin signaling. That makes metabolic health even more critical and may make certain dietary strategies like carbohydrate restriction particularly relevant. Since ketones can serve as an alternative brain fuel that bypasses that potentially disrupted insulin signaling pathway. Ultimately, science is a process. It advances when old paradigms give way to new evidence, and when honest researchers are willing to follow the data wherever it leads, even when it may be uncomfortable. The story of Alzheimer's research over the past few decades is a cautionary tale about what can happen when a field becomes too invested in a single theory. The metabolic theory of Alzheimer's does something the plaque theory struggled to do. It really tells a complete mechanistic story from cell biology through epidemiology. It connects all the dots and because of this, it opens the door for what I think will be much more meaningful findings and interventions in the future. Thanks for joining me in the metabolic classroom. If you found this valuable, please share it with someone you care about. Remember, more knowledge, better health.

[Instacart / Workday Advertisement Voice]

Could AI help you do more of what you love? Workday is the next gen ERP powered by AI that actually knows your business. We help you handle the have to dos so you can focus on the can't wait to dos. It's a new work day.

[Skyrizi Advertisement Voice]

My son loves to fly kites, but my active psoriatic arthritis can sometimes hold me back. Now with Skyrizi to treat my skin and joints, I'm ready to go. Skyrizi Risankizumab RZA a prescription only 150mg injection for adults. Helps with less joint pain, stiffness, swelling and fatigue. For those who also have plaque psoriasis, 90% clearer skin is possible with just four doses a year. After two starter doses,

[Instacart / Workday Advertisement Voice]

don't use if allergic to Skyrizi. Serious allergic reactions and an increased risk of infections or a lower ability to fight them may occur. Before treatment, your doctor should check for infection and tuberculosis. Tell your doctor if you have an infection or symptoms such as fever, sweats, chills, muscle aches or cough, or if you plan to or recently received a vaccine.

[Skyrizi Advertisement Voice]

With Skyrizi, there's nothing like clearer skin and better movement. And that means everything. Ask your doctor about Skyrizi today and visit skyrizi.com or call 1-866-Skyrizi to learn more.

[Capital One Bank Spokesperson]

With no fees or minimums on checking accounts, it's no wonder the Capital One bank guy is so passionate about banking with Capital One. If he were here, he wouldn't just tell you about no fees or minimums. He'd also talk about how most Capital One cafes are open seven days a week to assist assist with your banking needs. Yep, even on weekends, it's pretty much all he talks about in a good way. What's in your wallet terms apply see capitalone.com bank capital1NA member FDIC.